REFERENCES
- Kramer H, Molitch M. Screening for kidney disease in adults with diabetes. Diabetic Care. 2005;28:1813–1816.
- Futrakul N, Futrakul P. Diabetic nephropathy: Current concept of therapeutic strategy toward self-sufficiency. Nephrol Therap. 2011, doi:10.4172/2161-0959.S2-002.
- Mann JF, Schmieder RE, Mc Queen M, . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The DN TARGET STUDY): A multicentre, randomized, double blind, controlled final. Lancet. 2008;372(9638):547–553.
- Futrakul N, Futrakul P. Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes. Int J Vasc Med. 2011;2011(2011), Article ID 971524.
- Futrakul P, Yenrudi S, Futrakul N, . Tubular function and tubulointerstitial disease. Am J Kidney Dis. 1999;33:886–891.
- Deekajorndech T. A biomarker for detecting early tubulointerstitial disease and ischemia in glomerulonephropathy. Ren Fail. 2007;29:1013–1017.
- Futrakul N, Futrakul P. Indices indicating early renal microvascular disease in diabetes. Open Biomarkers J. 2011;4:18–20.
- Futrakul N, Kulaputana O, Futrakul P, . Enhanced peritubular capillary flow and renal function can be accomplished in normoalbuminuria type 2 diabetic nephropathy. Ren Fail. 2011;33:213–315.
- Ritt M, Ott C, Raff U, . Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis. 2009;53:281–289.